Cognition Therapeutics Holds Meeting with FDA to Discuss Zervimesine
Cognition Therapeutics conducted a Type C meeting with the U.S. Food and Drug Administration on January 21, 2026. The objective of this meeting was to review plans for the proposed Phase 2b study of zervimesine in dementia with Lewy bodies, a disease with no FDA-approved therapies. "We had a productive meeting with the FDA, during which we discussed clinically meaningful endpoints for the next Phase 2b study of mild-to-moderate DLB," stated Anthony O. Caggiano, MD, PhD, Cognition's chief medical officer. "We look forward to receiving meeting minutes later this quarter and continuing our dialogue with the FDA to advance clinical development in DLB."
Discover Tomorrow's Bullish Stocks Today
Analyst Views on CGTX
About CGTX
About the author
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO
Biotech Gains in After-Hours Trading: Several small- and mid-cap biotech and healthcare companies saw significant gains in after-hours trading, driven by corporate updates and financing developments.
SeaStar Medical's Leadership Change: SeaStar Medical's stock rose nearly 10% after the appointment of Michael Messinger as Chief Financial Officer, boosting investor confidence despite no new news.
Cognition Therapeutics' Speculative Buying: Cognition Therapeutics rebounded almost 11% in after-hours trading, likely due to speculative buying interest, following a decline during regular trading hours.
Mesoblast's Revenue Projection: Mesoblast's shares increased after management projected over $30 million in gross revenue for the December quarter, indicating strong demand for its cell therapy product, Ryoncil.
